Georgia M. Beasley, Ketan Sharma, Joyce Wong, Mike Miller, Ryan S. Turley, Michael Lidsky, Melanie Masoud, Mark W. Dewhirst, Paul J. Mosca, Jonathan S. Zager and Douglas S. Tyler A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion Cancer 118
Version of Record online: 6 JUN 2012 | DOI: 10.1002/cncr.27676
Although studies of melphalan-based isolated limb infusion (ILI) combine data from upper extremity treatments with data from lower extremity treatments, differences between the 2 may be clinically important. The upper extremity appears to be relatively resistant to the toxic effects of melphalan-based ILI as it is currently performed, suggesting a potential for further optimization of drug dosing for upper extremity ILI.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field